Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Collaboration Announcement

11 Apr 2013 16:44

RNS Number : 1781C
Advanced Oncotherapy PLC
11 April 2013
 



ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or "the Company")

 

COLLABORATION ANNOUNCEMENT

 

Advanced Oncotherapy (AVO) is pleased to announce a newly established synergy collaboration between CERN and Application of Detectors and Accelerators to Medicine SA ("ADAM") .

 

A team of experts in accelerator and detector technology from CERN founded ADAM with Italian entrepreneur Dr Alberto Colussi in 2007. ADAM aims to capitalise on the know-how and infrastructure that CERN provides to build innovative accelerators for proton therapy and for conventional radiotherapy.

 

ADAM's research and development activities have focused on two main fields: the design and construction of compact linear accelerators for conventional radiotherapy, and of compact linear accelerators for proton therapy. The next phase of the collaboration, a newly established synergy between ADAM,CERN and AVO will complete the Proton Beam accelerator complex.

 

"For CERN the transfer of technology and know-how in the medical field is an important part of the impact of basic science on societal issues," says CERN Director of Accelerators and Technology Steve Myers. "This partnership is a pragmatic way to share our competences and know-how with industrial partners who are able to bring this innovative medical solution to the market."

 

 

For further information, please contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson,

Advanced Oncotherapy Group Plc

Libertas Capital Corporate Finance Ltd

Peterhouse Corporate Finance

Tavistock Communications

0203 617 8739

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

020 7569 9650

020 7469 0930

020 7920 3150

 

 

 

About Advanced Oncotherapy

 

Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments. These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector. Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on non-melanoma skin cancer and early stage breast cancer. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK. They have secured planning approval for its first proton beam therapy center in the UK in the City of London. In 2011, over 70,000 patients were treated worldwide with proton beam therapy in 32 centres.

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDSXSBBGXB
Date   Source Headline
26th Apr 20177:00 amRNSConversion of Convertible Loan Notes
25th Apr 20175:48 pmRNSAdditional financing agreement
25th Apr 20177:00 amRNSDirector/PDMR Shareholding
18th Apr 20177:00 amRNSConversion of loan notes
13th Apr 20177:00 amRNSDirector Dealing
11th Apr 20177:00 amRNSConversion of loan notes
7th Apr 20177:00 amRNSConversion of loan notes
6th Apr 20172:07 pmRNSTotal Voting Rights
4th Apr 20174:01 pmRNSDirector Dealing
4th Apr 201710:05 amRNSDirector Dealing - Replacement
4th Apr 20177:00 amRNSDirector Dealing
31st Mar 20175:10 pmRNSResult of General Meeting
27th Mar 20177:00 amRNSAdditional financing agreement
21st Mar 20177:00 amRNSHolding(s) in Company
15th Mar 20177:15 amRNSHardman Research: Delivery of LIGHT
10th Mar 20177:00 amRNSPosting of Circular, Notice of GM and Update
6th Mar 20173:30 pmRNSInvestor presentation and Update
28th Feb 20177:00 amRNSConversion of convertible loan notes
24th Feb 20177:00 amRNSUpdate on financing and Harley Street
22nd Feb 20177:00 amRNSFinancing agreement
16th Feb 20177:00 amRNSInvestor presentation
8th Feb 20177:00 amRNSSignificant shareholder
6th Feb 20177:00 amRNSSinophi update
26th Jan 20177:00 amRNSDirectorate Changes
24th Jan 20177:00 amRNSSinophi Update
23rd Jan 20177:00 amRNSNon-dilutive financing plan update
3rd Jan 201711:41 amRNSDirector Dealing
29th Dec 20162:13 pmRNSDirector Dealing
29th Dec 201612:51 pmRNSSignificant Shareholding Dealing
22nd Dec 20161:36 pmRNSDirector Dealing
22nd Dec 20167:00 amRNSFurther progress in LIGHT technical development
21st Dec 201611:47 amRNSDirector Dealing
21st Dec 20167:00 amRNSDirector Dealing
20th Dec 20167:00 amRNSDirector dealing
15th Dec 20167:00 amRNSVideo of LIGHT system and testing facilities
30th Nov 20163:39 pmRNSOperational Update
29th Nov 201611:29 amRNSDirector Dealing - replacement
29th Nov 201610:06 amRNSDirector Dealing
24th Nov 20164:24 pmRNSUpdate on Harley Street and Sinophi
15th Nov 20165:45 pmRNSHolding(s) in Company
8th Nov 20167:00 amRNSChange of Adviser
7th Nov 20162:55 pmRNSExercise of Options and Issue of Shares
1st Nov 20167:00 amRNSDirectorate Change
1st Nov 20167:00 amRNSResult of Open Offer
31st Oct 20167:00 amRNSIndustrialisation agreement with Thales
27th Oct 20167:00 amRNSDirectorate Change
25th Oct 20164:59 pmRNSREPLACEMENT: Director Dealing
25th Oct 20163:01 pmRNSDirector Dealing
19th Oct 20167:00 amRNSHarley Street planning permission granted
14th Oct 20167:00 amRNSOpen Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.